Имплементация системы поддержки принятия решений персонализации режима дозирования бромдигидрохлорфенилбензодиазепина у пациентов с синдромом отмены алкоголя, основанной на фармакогенетических биомаркерах
https://doi.org/ 10.25557/2073-7998.2019.01.13-24
Аннотация
Ключевые слова
Об авторах
М. С. ЗастрожинРоссия
А. С. Сорокин
Россия
Т. В. Агибалова
Россия
И. А. Бедина
Россия
Е. А. Гришина
Россия
А. П. Антоненко
Россия
И. Н. Розочкин
Россия
Т. Е. Галактионова
Россия
И. В. Барна
Россия
В. Ю. Скрябин
Россия
А. В. Орлова
Россия
А. Д. Агузаров
Россия
Л. М. Савченко
Россия
Е. А. Брюн
Россия
Д. А. Сычев
Россия
Список литературы
1. Sachdeva A., Choudhary M., Chandra M. Alcohol Withdrawal Syndrome: Benzodiazepines and Beyond. J. Clin. Diagn. Res. 2015; 9 (9): VE01-VE07. doi: 10.1016/j.drugalcdep.2005.04.011.
2. Weintraub S.J. Diazepam in the Treatment of Moderate to Severe Alcohol Withdrawal. CNS Drugs 2017; 31 (2): 87-95. doi: 10.1007/s40263-016-0403-y.
3. Kattimani S., Bharadwaj B. Clinical management of alcohol withdrawal: A systematic review. Ind. Psychiatry J. 2013; 22 (2): 100-108. doi: 10.4103/0972-6748.132914.
4. Mayo-Smith M.F. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. JAMA 1997; 278 (2): 144-151.
5. Dean L. Diazepam Therapy and CYP2C19 Genotype. Medical Genetics Summaries. Bethesda (MD): National Center for Biotechnology Information (US) 2012.
6. Inomata S., Nagashima A., Itagaki F. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin. Pharmacol. Ther. 2005; 78: 647-655. doi: 10.1016/j.clpt.2005.08.020.
7. Singh A.B. Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report. Clinical Psychopharmacology and Neuroscience 2015; 13 (2): 150-156. doi:10.9758/cpn.2015.13.2.150.
8. Fagerness J., Fonesca E., Hess G.P. Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. The Amercian Journal of Managed Care 2014; 20 (5): e146-e156.
9. Brener S., Holubowich C. Pharmacogenomic Testing for Psychotropic Medication Selection: A Systematic Review of the Assurex GeneSight Psychotropic Test. Ontario Health Technology Assessment Series 2017; 17 (4): 1-39.
10. Elliott L.S., Henderson J.C., Neradilek M.B., Moyer N.A., Ashcraft K.C., Thirumaran R.K. Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial. PLoS One 2017; 12 (2): e0170905.
11. Bousman C.A., Hopwood M. Commercial Pharmacogenetic - Based Decision-Support Tools in Psychiatry. The Lancet Psychiatry 2016; (3): 585-590. doi: 10.1016/S2215-0366(16)00017-1.
12. Hua T., Quertermous T., Beatriz R., Sharon L.R., Xiaofeng Z., Brown A., Pankow J.S., Province M.A., Hunt S.C., Boerwinkle E., Schork N.J., Risch N.J. Genetic Structure, Self-Identified Race/Ethnicity, and Confounding in Case-Control Association Studies. American Journal of Human Genetics 2005; 76: 268-275. doi: 10.1086/427888.
13. Sullivan J.T., Sykora K., Schneiderman J., Naranjo C.A., Sellers E.M. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br. J. Addict. 1989; 84 (11): 1353-1357.
14. Bharadwaj B., Kattimani S. Clinical management of alcohol withdrawal: A systematic review. Industrial Psychiatry Journal 2013; 2 (22): 100-108.
15. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983; 67 (6): 361-370.
16. Busner J., Targum S.D. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 2007; 4 (7): 28-37.
17. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. Suppl 1987; 334: 1-100.
Рецензия
Для цитирования:
Застрожин М.С., Сорокин А.С., Агибалова Т.В., Бедина И.А., Гришина Е.А., Антоненко А.П., Розочкин И.Н., Галактионова Т.Е., Барна И.В., Скрябин В.Ю., Орлова А.В., Агузаров А.Д., Савченко Л.М., Брюн Е.А., Сычев Д.А. Имплементация системы поддержки принятия решений персонализации режима дозирования бромдигидрохлорфенилбензодиазепина у пациентов с синдромом отмены алкоголя, основанной на фармакогенетических биомаркерах. Медицинская генетика. 2019;18(1):13-24. https://doi.org/ 10.25557/2073-7998.2019.01.13-24
For citation:
Zastrozhin M.S., Sorokin A.S., Agibalova T.V., Bedina I.A., Grishina E.A., Antonenko A.P., Rozochkin I.N., Galaktionova T.E., Barna I.V., Skryabin V.Yu., Orlova A.V., Aguzarov A.D., Savchenko L.M., Bryun E.A., Sychev D.A. Expirience of implementation of personalized clinical decision support system for dosing of bromdihydrochlorphenylbenzodiazepine in patients with alcohol withdraw syndrome based on the pharmacogenomic markers. Medical Genetics. 2019;18(1):13-24. (In Russ.) https://doi.org/ 10.25557/2073-7998.2019.01.13-24